News

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Priority Health is acquiring 52,000-member Physicians Health Plan of Northern Indiana.

EndeavorOTC costs $24.99 monthly or $129.99 annually.

Physicians in a new survey by the American Medical Association said prior authorization leads to delayed care and a high administration burden for physician practices.

Adherence measures developed by the Pharmacy Quality Alliance (PQA) are an important part of the Medicare Part D Star Ratings program. PQA has launched a Health Equity Technical Expert Panel to provide input on specific approaches to ensuring PQA’s measures support equitable health care.

In a recent announcement, the virtual healthcare provider shared the expansion can offer patients access to a number of clinical services with standard copays, ensuring they receive affordable, high-quality primary care whenever needed.

Congressional Budget Office analysts say that Medicaid unwinding, immigration and scheduled end of ACA premium subsidies are factors in the increase.

A recent industry survey conducted by HealthEdge provides insight into how health insurance consumers in the United States feel about their current coverage.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

Even though value-based care has been talked about for a long time, it may not be the end.

In 2024, there have been two common health plan issues brought up by employers.

Harvard researcher Zirui Song says research findings show that nospitals higher prices and lower quality.

Type 2 diabetes patients ages 10 and up can now take Farxiga.

Three speakers, three different takes on the state of U.S. healthcare and what ails it.

In an interview prior to the AHIP 2024 conference in Las Vegas, MHE spoke with Sachin H. Jain, M.D.,MBA, CEO, SCAN Group and SCAN Health Plan, who acknowledged that while SCAN isn't perfect, they are ahead in simplifying healthcare by recognizing their role in the problem.

CDC Director Mandy K. Cohen spabout the agency modernizing data and working with payers and other parts of the healthcare system at the AHIP meeting in Las Vegas.

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about how GLP-1 agonist drugs like Wegovy and Zepbound are changing the paradigm for weight loss.

Study results may change the understanding and treatment of hormone-based treatment of primary ovarian insufficiency based on genetics.

Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.

An updated draft guidance says that promotional materials that suggest a biosimilar or reference product is superior “are likely to be false or misleading.” The agency has also warned against making comparisons between biosimilars and those with the interchangeable designation.

Merith Basey, executive director of Patients for Affordable Drug, talks about strategies for lowering the cost of new drugs, especially cell and gene therapy, in a second part of a video interview conducted prior to the June 11-13 AHIP 2024 meeting in Las Vegas.

Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies, in an interview with MHE previewing the presentation she's co-presenting on June 11 at the AHIP 2024 meeting in Las Vegas.

Elafibranor is the first new medicine approved for primary biliary cholangitis in nearly a decade.

In a randomized clinical trial, the effectiveness of a stepped-care model for delivering palliative care to patients with advanced lung cancer was evaluated.

The FDA approved the expanded age indication for the RSV drug to ages 50 to 59 this past Friday, after initially being approved in the U.S. in May 2023 for RSV patients ages 60 and older.

Rytelo is the first and only telomerase inhibitor approved by the FDA and is expected to be available by the end of summer 2024.

A new report aims to create consistency out of a number of observations about associations between echocardiographic values by analyzing them in the context of real-world patient outcomes.

Progentos will use the funding to advance its multiple sclerosis (MS) program through human proof of concept clinical studies and expand its small molecule pipeline to other degenerative conditions.